- Home
- HDSN vs ZNTL Comparison
HDSN vs ZNTL Comparison
Compare HDSN & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HDSN
- ZNTL
- Stock Information
- Founded
- HDSN 1991
- ZNTL 2014
- Country
- HDSN United States
- ZNTL United States
- Employees
- HDSN N/A
- ZNTL N/A
- Industry
- HDSN Industrial Specialties
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- HDSN Consumer Discretionary
- ZNTL Health Care
- Exchange
- HDSN Nasdaq
- ZNTL Nasdaq
- Market Cap
- HDSN 337.8M
- ZNTL 105.8M
- IPO Year
- HDSN 1994
- ZNTL 2020
- Fundamental
- Price
- HDSN $8.20
- ZNTL $1.24
- Analyst Decision
- HDSN Buy
- ZNTL Buy
- Analyst Count
- HDSN 4
- ZNTL 7
- Target Price
- HDSN $7.44
- ZNTL $8.60
- AVG Volume (30 Days)
- HDSN 405.0K
- ZNTL 1.4M
- Earning Date
- HDSN 08-05-2025
- ZNTL 08-08-2025
- Dividend Yield
- HDSN N/A
- ZNTL N/A
- EPS Growth
- HDSN N/A
- ZNTL N/A
- EPS
- HDSN 0.38
- ZNTL N/A
- Revenue
- HDSN $227,211,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- HDSN N/A
- ZNTL N/A
- Revenue Next Year
- HDSN $9.07
- ZNTL N/A
- P/E Ratio
- HDSN $21.65
- ZNTL N/A
- Revenue Growth
- HDSN N/A
- ZNTL N/A
- 52 Week Low
- HDSN $5.11
- ZNTL $1.01
- 52 Week High
- HDSN $9.28
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- HDSN 66.60
- ZNTL 44.51
- Support Level
- HDSN $7.78
- ZNTL $1.13
- Resistance Level
- HDSN $8.39
- ZNTL $1.39
- Average True Range (ATR)
- HDSN 0.26
- ZNTL 0.12
- MACD
- HDSN 0.03
- ZNTL -0.03
- Stochastic Oscillator
- HDSN 83.62
- ZNTL 26.83
About HDSN Hudson Technologies Inc.
Hudson Technologies Inc is an American industrial products manufacturer. It develops products which are mainly used in commercial air conditioning, industrial processing, and refrigeration systems. The company products include refrigerant and industrial gases, refrigerant management services and RefrigerantSide services, which consist of system decontamination. These are performed at customer's site using its Zugibeast system, which is a fast and portable system and allows the R-Side services team to accelerate critical services while saving customers time, money and aggravation. The company also owns a web-based real-time monitoring service which is used in the facility's refrigeration systems and other energy systems.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.